Valneva Se - 辉瑞计划在2026年向美国FDA提交生物许可证申请和向欧洲药品管理局提交上市授权申请
Valneva Se - 辉瑞计划在2026年向美国FDA提交生物许可证申请和向欧洲药品管理局提交上市授权申请
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.